ULTRAGENYX PHARMACEUTICAL INC.: 10-Q filed 2025-08-06
What ULTRAGENYX PHARMACEUTICAL INC. reported in its quarterly report filed 2025-08-06 (fiscal Q2 2025): 41 published measures, 113 facts as tagged in accession 0000950170-25-103290.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-08-06
- Fiscal period
- fiscal Q2 2025
- Accession
- 0000950170-25-103290 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ULTRAGENYX PHARMACEUTICAL INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 1,306,265,000 | USD | |
| At 2024-12-31 | 1,503,456,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 1,147,979,000 | USD | |
| At 2024-12-31 | 1,241,159,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 151,286,000 | USD | |
| At 2025-03-31 | 144,246,000 | USD | |
| At 2024-12-31 | 255,297,000 | USD | |
| At 2024-06-30 | 432,418,000 | USD | |
| At 2024-03-31 | 140,264,000 | USD | |
| At 2023-12-31 | 275,414,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 176,306,000 | USD | |
| At 2024-12-31 | 173,729,000 | USD | |
| At 2024-06-30 | 480,693,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -114,951,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -266,031,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -131,598,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -302,282,000 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | -274,748,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | -267,690,000 | USD | 182 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 3,784,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 5,220,000 | USD | 182 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 166,496,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 305,788,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 147,026,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 255,859,000 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 83,806,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 384,881,000 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 191,065,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 154,999,000 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | -4,222,875,000 | USD | |
| At 2024-12-31 | -3,956,844,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 98,460,445 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 97,381,745 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 86,580,516 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 85,433,443 | shares | 182 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 98,460,445 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 97,381,745 | shares | 181 |
| 2024-04-01 to 2024-06-30 | 86,580,516 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 85,433,443 | shares | 182 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -1.17 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -2.73 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -1.52 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -3.54 | USD/shares | 182 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -1.17 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -2.73 | USD/shares | 181 |
| 2024-04-01 to 2024-06-30 | -1.52 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -3.54 | USD/shares | 182 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 947,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 2,257,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 858,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 1,313,000 | USD | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 255,763,000 | USD | |
| At 2024-12-31 | 265,929,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -107,888,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -250,827,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -116,361,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -281,708,000 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 719,788,000 | USD | |
| At 2024-12-31 | 817,123,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 293,244,000 | USD | |
| At 2024-12-31 | 344,153,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 34,242,000 | USD | |
| At 2024-12-31 | 38,756,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 44,406,000 | USD | |
| At 2024-12-31 | 44,406,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 124,464,000 | USD | |
| At 2024-12-31 | 121,801,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 46,498,000 | USD | |
| At 2024-12-31 | 45,007,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 86,646,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 174,443,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 80,604,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 158,764,000 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 164,736,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 330,508,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | 161,503,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 339,990,000 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 96,353,634 | shares | |
| At 2024-12-31 | 92,484,330 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 4,374,333,000 | USD | |
| At 2024-12-31 | 4,212,692,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | -268,000 | USD | |
| At 2024-12-31 | -643,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 174,733,000 | USD | |
| At 2024-12-31 | 178,314,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 60,121,000 | USD | |
| At 2024-12-31 | 62,680,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 17,398,000 | USD | |
| At 2024-12-31 | 17,082,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 180,792,000 | USD | |
| At 2024-12-31 | 240,973,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 61,241,000 | USD | |
| At 2024-12-31 | 40,290,000 | USD |
Net deferred tax liabilities
Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-06-30 | 30,058,000 | USD | |
| At 2024-12-31 | 30,058,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -114,004,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -263,774,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -130,740,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -300,969,000 | USD | 182 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | -114,878,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -265,656,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -132,262,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -304,024,000 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 17,609,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 17,707,000 | USD | 182 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-06-30 | 2,140,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 2,977,000 | USD | 181 |
| 2024-04-01 to 2024-06-30 | -1,829,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -3,434,000 | USD | 182 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 2,591,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 22,750,000 | USD | 182 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-06-30 | 555,000 | USD | 181 |
| 2024-01-01 to 2024-06-30 | 6,251,000 | USD | 182 |
Inspect the source
- Entity
- ULTRAGENYX PHARMACEUTICAL INC. / CIK 0001515673
- Captured
- 2026-09-20T09:13:41.216Z
- SEC response SHA-256
3388baa10c986fcc5de3f265870d6dbd0a3e1dda1bcd7ba6dcbc8c72254b9c41
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001515673.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))